Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication

Summary

This study is designed to determine whether LLG783 displays the clinical safety and efficacy profile, after multiple i.v. doses, to support further development in patients with PAD and intermittent claudication.

Timeline

Start

2017-09-20

Primary completion

2018-09-07

Completion

2018-12-27

Outcome

Missed primary endpoint

registry analysis (superiority test); LLG783 6mg/kg vs Placebo; p = 0.2612; Mean Difference (Final Values) -17.74 NCT03194776 ↗

Drugs

Indications